PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32808031-9 2020 Thus, our findings suggest that tofacitinib is quite effective in protecting from colitis by inhibition of a bundle of T cell derived cytokines like IL-5, IL-6, IL-9, IL-13 and IL-17A. tofacitinib 32-43 interleukin 6 Homo sapiens 155-159 31560043-8 2020 Tofacitinib modulated the responses of activated monocytes toward a regulatory phenotype through reduced TNFalpha and IL-6 secretion and enhanced Treg induction in cocultures. tofacitinib 0-11 interleukin 6 Homo sapiens 118-122 31448433-5 2020 Upadacitinib (and tofacitinib) reversibly inhibited IL-6-induced pSTAT3 and IL-7-induced pSTAT5 in a concentration-dependent manner. tofacitinib 18-29 interleukin 6 Homo sapiens 52-56 31448433-6 2020 Model-estimated values of 50% of the maximum effect were 60.7 nM for upadacitinib and 119 nM for tofacitinib for IL-6-induced pSTAT3 inhibition, and 125 nM for upadacitinib and 79.1 nM for tofacitinib for IL-7-induced pSTAT5 inhibition. tofacitinib 97-108 interleukin 6 Homo sapiens 113-117 31448433-6 2020 Model-estimated values of 50% of the maximum effect were 60.7 nM for upadacitinib and 119 nM for tofacitinib for IL-6-induced pSTAT3 inhibition, and 125 nM for upadacitinib and 79.1 nM for tofacitinib for IL-7-induced pSTAT5 inhibition. tofacitinib 189-200 interleukin 6 Homo sapiens 113-117 31448433-7 2020 Tofacitinib 5 mg BID is estimated to have a similar magnitude of effect on IL-6-induced pSTAT3 to ~3 mg BID of upadacitinib (immediate-release formulation), whereas a 4-fold higher dose of upadacitinib (~12 mg BID), is estimated to show a similar magnitude of inhibition on IL-7-induced pSTAT5 as tofacitinb 5 mg BID. tofacitinib 0-11 interleukin 6 Homo sapiens 75-79 29790294-10 2018 Tofacitinib inhibited the effect of oncostatin M (OSM) on interleukin-6 (IL-6) and monocyte chemotactic protein 1 and reversed the effects of OSM on RASF cellular metabolism. tofacitinib 0-11 interleukin 6 Homo sapiens 58-71 31448433-2 2020 This study characterizes the relationships between upadacitinib exposure and interleukin (IL)-6-induced signal transducer and activator of transcription proteins 3 (STAT3) phosphorylation (pSTAT3) and IL-7-induced STAT5 phosphorylation (pSTAT5) in the ex vivo setting as measures for JAK1 and JAK1/JAK3 inhibition, respectively, with comparison to tofacitinib. tofacitinib 348-359 interleukin 6 Homo sapiens 77-95 31780862-6 2019 Serum IL-35 levels were significantly increased and serum levels of TNF-alpha, IL-17, IL-6, and IFN-gamma were significantly reduced in response to tofacitinib since week 4. tofacitinib 148-159 interleukin 6 Homo sapiens 86-90 30984167-12 2019 Results: Tofacitinib and baricitinib decreased the IL-6 release of RASF stimulated with oncostatin M. tofacitinib 9-20 interleukin 6 Homo sapiens 51-55 29790294-10 2018 Tofacitinib inhibited the effect of oncostatin M (OSM) on interleukin-6 (IL-6) and monocyte chemotactic protein 1 and reversed the effects of OSM on RASF cellular metabolism. tofacitinib 0-11 interleukin 6 Homo sapiens 73-77 28927890-5 2018 Tofacitinib and etanercept commonly reduced IL-6, CCL20, and CXCL10, but IL-17A was significantly reduced only in responders of either treatment. tofacitinib 0-11 interleukin 6 Homo sapiens 44-48 29162613-7 2018 By contrast, ruxolitinib failed to suppress the repression of drug-detoxifying protein mRNA levels caused by IL-1beta The JAK inhibitor and anti-rheumatoid arthritis compound tofacitinib was additionally found to reverse IL-6-mediated suppression of P450 and transporter mRNA expressions. tofacitinib 175-186 interleukin 6 Homo sapiens 221-225 29106440-9 2018 In vitro, these cytokines increased MSI in colon epithelial cells, and the Janus kinase (JAK) inhibitor tofacitinib abolished IL-6-induced or PMN-induced MSI. tofacitinib 104-115 interleukin 6 Homo sapiens 126-130 27003097-4 2016 Like tofacitinib, tocilizumab, a biologic targeting the IL-6 pathway, has been approved for use in rheumatoid arthritis and interest in transplantation has been confined to several investigator-initiated trials. tofacitinib 5-16 interleukin 6 Homo sapiens 56-60 28752178-7 2017 Tofacitinib significantly down-regulated CTS-induced expression of ADAMTS4, ADAMTS5, MMP13, and RUNX2, and the release of IL-6 in supernatant by chondrocytes. tofacitinib 0-11 interleukin 6 Homo sapiens 122-126 28570653-6 2017 RESULTS: AIT combined with short-term TOFA administration was significantly more effective in suppressing total cell and eosinophil infiltration into the lung, local cytokine production including IL-1beta and CXCL1 and showed a trend for the reduction of IL-4, IL-13, TNF-alpha and IL-6 compared to AIT alone. tofacitinib 38-42 interleukin 6 Homo sapiens 282-286 28570653-7 2017 Furthermore, TOFA co-administration significantly reduced systemic IL-6, IL-1beta and OVA-specific IgE levels and induced IgG1 to the same extent as AIT alone. tofacitinib 13-17 interleukin 6 Homo sapiens 67-71 26353790-10 2016 In PsA explant, tofacitinib significantly decreased spontaneous secretion of IL-6, IL-8, MCP-1, MMP9/MMP2, MMP3 (all p<0.05) and decreased the MMP3/TIMP3 ratio (p<0.05), with no effect observed for IP-10 or IL-10. tofacitinib 16-27 interleukin 6 Homo sapiens 77-81 24342887-9 2014 Transcripts encoding interleukin (IL)-1beta and IL-6 were significantly decreased by tofacitinib treatment at post-thermocautery day 3. tofacitinib 85-96 interleukin 6 Homo sapiens 48-52 22121136-5 2012 RESULTS: Interleukin-6-induced phosphorylation of STAT1 and STAT3 was inhibited by CP-690,550 with IC(50) values of 23 and 77 nM, respectively. tofacitinib 83-89 interleukin 6 Homo sapiens 9-22 24665995-0 2014 Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis. tofacitinib 34-45 interleukin 6 Homo sapiens 81-94 24665995-5 2014 Tofacitinib was also associated with reduced serum interleukin (IL)-6, but had no effect on serum levels of soluble IL-6 receptor. tofacitinib 0-11 interleukin 6 Homo sapiens 51-69 24665995-8 2014 These results suggest that tofacitinib down-regulates the proinflammatory cytokine, IL-6, accompanied by reduced serum SAA levels in patients with active RA. tofacitinib 27-38 interleukin 6 Homo sapiens 84-88 24665995-9 2014 The ability to regulate elevated serum IL-6 and SAA levels may explain the anti-inflammatory activity of tofacitinib. tofacitinib 105-116 interleukin 6 Homo sapiens 39-43 22147632-8 2012 Treatment of SCID-HuRAg mice with tofacitinib decreased serum levels of human IL-6 and IL-8 and markedly suppressed invasion of synovial tissue into cartilage. tofacitinib 34-45 interleukin 6 Homo sapiens 78-82 22147632-9 2012 CONCLUSION: Tofacitinib directly suppressed the production of IL-17 and IFNgamma and the proliferation of CD4+ T cells, resulting in inhibition of IL-6 production by RASFs and IL-8 production by CD14+ cells and decreased cartilage destruction. tofacitinib 12-23 interleukin 6 Homo sapiens 147-151 22941906-10 2012 CP-690,550 significantly decreased the expression of interleukin-6 in synovial macrophages. tofacitinib 0-6 interleukin 6 Homo sapiens 53-66 22147632-5 2012 RESULTS: Tofacitinib treatment of CD4+ T cells originating from synovium and peripheral blood inhibited the production of interleukin-17 (IL-17) and interferon-gamma (IFNgamma) in a dose-dependent manner, affecting both proliferation and transcription, but had no effect on IL-6 and IL-8 production. tofacitinib 9-20 interleukin 6 Homo sapiens 274-278 22147632-7 2012 However, conditioned medium from CD4+ T cells cultured with tofacitinib inhibited IL-6 production by RASFs and IL-8 production by CD14+ monocytes. tofacitinib 60-71 interleukin 6 Homo sapiens 82-86 22460142-7 2012 Tofacitinib reduced serum levels of human IL-6 and IL-8 in the mice and also reduced synovial inflammation and invasion into the implanted cartilage. tofacitinib 0-11 interleukin 6 Homo sapiens 42-46 34660145-3 2021 Tofacitinib is an effective JAK1 and JAK3 inhibitor that can block several cytokines such as IL-2, IL-7, and IL-6. tofacitinib 0-11 interleukin 6 Homo sapiens 109-113 34107055-5 2021 Tofacitinib impairs IL-6/IFN/LPS-induced STAT1 and STAT3 phosphorylation in RA MPhis and FLS. tofacitinib 0-11 interleukin 6 Homo sapiens 20-24 35536531-4 2022 Tofacitinib significantly inhibited expression of pro-inflammatory factors including tumor necrosis factor-alpha (TNF-alpha), vascular endothelial growth factor A, matrix metalloproteinase 1, matrix metalloproteinase 3, interleukin-6 and interferon gamma in RA-FLS cells. tofacitinib 0-11 interleukin 6 Homo sapiens 220-233 35631449-0 2022 Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF-beta and IL-6. tofacitinib 0-11 interleukin 6 Homo sapiens 123-127 33216905-10 2021 ATG5-deficient 3D-acini reproduced the findings observed in LSG from pSS patients, showing increased expression of pro-inflammatory markers such as IL-6, which was reversed by tofacitinib. tofacitinib 176-187 interleukin 6 Homo sapiens 148-152 33216905-0 2021 Tofacitinib counteracts IL-6 overexpression induced by deficient autophagy: implications in Sjogren"s syndrome. tofacitinib 0-11 interleukin 6 Homo sapiens 24-28 34052462-0 2021 The JAK Inhibitor Tofacitinib Inhibits Structural Damage in Osteoarthritis by Modulating JAK1/TNF-alpha/IL-6 Signaling Through Mir-149-5p. tofacitinib 18-29 interleukin 6 Homo sapiens 104-108 34052462-6 2021 Tofacitinib-treated C20A4 and C28/I2 cells had a significantly lower expression of JAK/IL-6/TNF-alpha and an increased level of miR-149-5p. tofacitinib 0-11 interleukin 6 Homo sapiens 87-91 34052462-7 2021 Notably, tofacitinib treatment reduced AC hypertrophy and secretion of RANKL and IL-6. tofacitinib 9-20 interleukin 6 Homo sapiens 81-85 33165509-8 2021 Tofacitinib induced stronger inhibition of inflammatory cytokine release (IL-6, TNFalpha, IL-12, IL-23) in UC compared with CD monocytes. tofacitinib 0-11 interleukin 6 Homo sapiens 74-78 33899926-5 2021 Tofacitinib down-regulated inflammatory cytokines by stimulated B (IL-6 and TNF-alpha) and T (IFN-gamma, IL-17, or TNF-alpha) cells in the short term while a significant reduction of IL-17 and IL-6 levels in PBMC supernatant was also observed. tofacitinib 0-11 interleukin 6 Homo sapiens 67-71 33899926-5 2021 Tofacitinib down-regulated inflammatory cytokines by stimulated B (IL-6 and TNF-alpha) and T (IFN-gamma, IL-17, or TNF-alpha) cells in the short term while a significant reduction of IL-17 and IL-6 levels in PBMC supernatant was also observed. tofacitinib 0-11 interleukin 6 Homo sapiens 193-197 33871355-9 2021 Partial inhibition of JAK activation by sub-saturating doses of Tofacitinib specifically lowered the levels of STAT1 activation by IL-6. tofacitinib 64-75 interleukin 6 Homo sapiens 131-135 33495807-11 2021 The inhibition of SOCS3 significantly activated JAK1/STAT3 signaling, as well as enhancing the levels of TNF-alpha, IL-6 and IL-1beta, and promoting apoptosis, which was reversed by the JAK1 inhibitor Tofacitinib. tofacitinib 201-212 interleukin 6 Homo sapiens 116-120 32909045-9 2021 RESULTS: Tofacitinib corrected compromised barrier function upon PTPN2 loss in macrophages and/or IECs via normalization of (i) tight junction protein expression, (ii) excessive STAT3 signaling, and (iii) IL-6 and IL-22 secretion. tofacitinib 9-20 interleukin 6 Homo sapiens 205-209 33337450-11 2021 The application of the STAT3 inhibitor CP690,550 reduced the production of the IL-6 family and the formation of osteoclasts both in vitro and in vivo. tofacitinib 39-44 interleukin 6 Homo sapiens 79-83 33587766-2 2021 (1) Tofacitinib is an effective oral JAK 1/3 inhibitor that can block IL-2, IL-7 and IL-6 and is reported as an option for alopecia areata treatment. tofacitinib 4-15 interleukin 6 Homo sapiens 85-89